• Home
  • News
  • Captor Therapeutics has selected ICON as the CRO company to conduct the first phase of clinical trials under the CT-01 project

Captor Therapeutics ®


Captor Therapeutics has selected ICON as the CRO company to conduct the first phase of clinical trials under the CT-01 project


Captor Therapeutics, a biopharmaceutical company focused on the development of drugs based on Targeted Protein Degradation (TPD), has signed an agreement with Dublin-based ICON, a world leading healthcare intelligence and Clinical Research Organisation (CRO), to prepare and conduct the first phase of clinical trials of an innovative new anti-cancer drug under the CT-01 project.


The collaboration begins with the signing of a Start-Up Agreement (pl. Implementation Agreement) for the initial services required to prepare the study protocol and the conclusion of a full-scope agreement for a Phase I, open-label, dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CT-01 in patients with intermediate or advanced hepatocellular carcinoma. Simultaneously, the Master Service Agreement was executed, the purpose of which is to establish the terms and conditions of the collaboration between Captor and ICON regarding the provision by ICON of the full range of services related to the Phase I clinical trial for CT-01. Once the full range of services required for Phase I of this clinical trial has been established, a detailed Statement of Work (Service Order) will be entered into.

- The selection of a Clinical Research Organisation (CRO) partner is another milestone within the CT-01 project that brings us closer to the clinic. With the funds raised from the share issue, which has stabilised our cash position in the medium term, we can fully focus on this process. I would like to emphasise that ICON is a world leading CRO with more than 30 years of experience in the implementation of clinical trials of various phases, including in the field of oncology. Naturally, the initiation of clinical trials is dependent on the final results of the preclinical studies, comments Dr Tom Shepherd, CEO of Captor Therapeutics.

The aim of the CT-01 project is to design and develop a drug candidate for the treatment of hepatocellular carcinoma, allowing the elimination of cancer stem cells, through the induced degradation of an oncogenic transcription factor.


About Captor Therapeutics:

Captor Therapeutics is a biopharmaceutical company specialising in the development of breakthrough drugs based on Targeted Protein Degradation (TPD) technology for the treatment of diseases with high unmet medical needs. TPD enables innovative approaches to drug development that can focus on novel molecular targets thought to be untreatable using conventional drug development methods and provide new treatments for diseases where existing drugs do not provide optimal therapeutic benefit. Currently, Captor is developing drugs for incurable, severe diseases, including malignancies and autoimmune diseases.


More information on Captor Therapeutics can be found:

On the website: http://www.captortherapeutics.com

LinkedIn: @CaptorTherapeutics

Twitter: @CaptorTherapeu1